AbbVie and Alvotech have...

...settled their patent and trade secret disputes, ending a years-long legal battle over Alvotech’s Humira biosimilar. The drug, which Alvotech says has potential as an interchangeable biosimilar, could now launch as early as July 2023 pending FDA review, and Alvotech will pay licensing royalties to AbbVie. For the treatment of psoriasis, Humira holds preferred status for 64% of all insured lives. Virtually all covered lives have some form of access to Humira.

SOURCE: MMIT Analytics, as of 3/14/22